explore -WSS

explore

author：fashion 2025-08-23 18:38:54 - browse：1

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： What the US credit downgrade means for the economy, your finances

WSS

No plane should take off without an EpiPen onboard

5 important ways Henrietta Lacks changed medical science

AI models in health care face new federal disclosure requirements

Chemotherapy shortages won’t get better under Biden’s latest plan

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Vertex non

hotspot

explore

explore

Anesthesiologist group: stop taking Ozempic before surgery

Leukemia patients are helped by Syndax's new type of therapy

Alkermes shareholders re

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Virginia high school admissions case could be legal follow

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

ChatGPT in medicine: STAT answers readers' burning questions

What the US credit downgrade means for the economy, your finances

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Radiology is caught between AI's potential and concern for patients

entertainment

Pfizer plans to depart BIO

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Why sickle cell disease is getting the first CRISPR treatment

What causes an itch? Researchers may have solved the mystery

Radiology is caught between AI's potential and concern for patients

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

explore

entertainment

knowledge

explore